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Abstract. The aim of this research was to test the antibacterial activity of Pinus pinaster aqueous bark ex-
tract (PABE) and its basic components against multidrug-resistant isolates of Acinetobacter baumannii 
belonging to European clone I and II, isolated previously from the clinical outbreaks. The minimum 
bactericidal concentration of PABE against both clones of A. baumannii was 200 mg ml–1, while lower 
concentrations showed high antibacterial activity. After 24 h of treatment with 100, 50 or 10 mg ml–1 of 
extract, the reduction in the number of A. baumannii isolates belonging to European clone I and II was 
85.8 ± 2.5 %, 78.5 ± 1.1 %, 66.3 ± 2.5 % and 90.2 ± 1.7 %, 78.6 ± 1.2 %, 69.8 ± 0.7 %, respectively. Sev-
eral basic components: caffeic acid, catechin, epicatechin, gallic acid and vanillin, detected in the extract 
by high performance liquid chromatography, contributed to the antibacterial activity of the extract against 
both clones of A. baumannii. However, the antibacterial activity of extract was higher than that of each 
tested basic component suggesting that proanthocyanidins, which were present in quite a large amount in 
the extract, might have also contributed to the activity of the extract. Antibacterial activity of PABE against 
A. baumannii reveals that complex and inexpensive natural product might be useful in combat against natu-
rally competent bacteria that easily acquire resistance against antibiotics. 
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INTRODUCTION 
Bark extracts of P. pinaster (PBEs) have a long history of 
ethnomedicinal use.1 As a mixture of a large variety of 
substances, PBEs are reported to exhibit a wide range of 
biological activities, including antioxidative, antiinflama-
tory, antitumor, antiatherogenic, antiviral, antimicrobial, 
etc.2 In papers published thus far, different extraction 
procedures, using different solvents were applied, affect-
ing the composition of extracts and biological activity.  
Species of the genus Acinetobacter, like A. bau-
mannii are naturally competent3 and easily acquire DNA 
from the environment/other species. Therefore, it is not 
surprising that Acinetobacter spp. displays mechanisms 
of resistance to all existing antibiotic classes as well as a 
prodigious capacity to acquire new determinants of re-
sistance.4 A. baumannii is a nonfermentative, Gram-
negative, nonmotile, oxidase-negative coccobacillus which 
is found in many health care environments5 and is a very 
effective human colonizer. This species emerged over the 
last decade as a leading cause of hospital-acquired infec-
tions; there are numerous reports of multidrug-resistant 
(MDR) A. baumannii from hospitals around the world6 
including Croatia.7,8 Problems caused by A. baumannii in 
the hospital setting are emphasized by high degree of 
resistance to drying and disinfectants, leading to long-
term persistence and the occurrence of outbreaks in the 
hospital environment.6 Global outbreaks of infections 
caused by A. baumannii are also frequent.4 
Current concerns regarding inefficiency of antibi-
otics or deleterious effects of synthetic chemicals used 
for medical purposes have encouraged a worldwide 
research on natural products potentially useful in devel-
opment of alternative treatments for common and 
emerging pathogens. Research on natural products rep-
resents convenient strategy to find extracts and bioac-
tive compounds, based on which new, effective and less 
expensive treatments can be applied.9 The aim of this 
study was to determine the antibacterial and bactericidal 
activity of P. pinaster aqueous bark extract (PABE) and 
its components against MDR A. baumannii isolated 
from the clinical outbreaks. 
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EXPERIMENTAL 
Plant Material and Preparation of Extracts 
In Croatia Pinus pinaster is mostly planted in coastal 
region. For this research bark was collected from 15 
trees growing on the island of Rab. Bark samples from 
15 trees were randomly pooled to form 3 samples (barks 
collected from 5 trees in each sample), air dried at  
50–55 °C for eight days to constant weight and grinded 
to pieces (fraction < 1 mm) using Colortronic mill. 
Grinded bark (100 g) was extracted with 500 ml of 
water at 100 °C for 30 minutes. The aqueous extract 
was collected and grinded bark was once again extract-
ed with 500 ml of fresh water at 100 °C for 30 minutes. 
The first and second extract were pooled and dry-
powdered extract was prepared from aqueous extract by 
spray-drying at 200 °C. From 100 g of grinded bark 
approximately 10 g of powdered extract was obtained. 
For treatment of bacteria dry-powdered extract was 
solved in sterile distilled water. 
 
HPLC Analysis of Pinus pinaster Aqueous Bark 
Extract (PABE)  
The following substances were detected and quantified: 
caffeic acid (cas: 331-39-5), catechin (cas: 225937-10-0), 
epicatechin (cas: 490-46-0), ferulic acid (cas: 537-98-4), 
gallic acid (cas: 149-91-7), taxifolin (cas: 24198-97-8) 
and vanillin (cas: 121-33-5). Authentic standards were 
purchased from Fluka (Germany) and Sigma-Aldrich 
(Germany). High performance liquid chromatography 
analysis (HPLC) system (Shimadzu, SIL-20AC XR) 
equipped with a quaternary pump, multi-wave UV/Vis 
detector, autosampler, fraction collector and Kinetex 2.6u 
C18 100A column; (100 × 4,60 mm, Phenomenex) was 
used for all analyses. Absorbance was measured from 
200 nm to 400 nm. The injection volume was 20 μl and 
the flow rate 1.0 ml min–1 from 0–29 minute and 38–45 
minute, and 1.5 ml min–1 from 29–38 minute, at 30 °C. 
Elution profile consisted of solvent A (vol. ratio: deion-
ised H2O : H3PO4 = 999 : 1) and solvent B (vol. ratio: 
methanol : H3PO4 = 999 : 1). The solvent composition 
(A/B) changed according to the following gradient: 
97/3 at 0 min, 97/3 at 2 min, 85/15 at 6 min, 84/16/0 at 
15 min, 82/18 at 29 min, 47/53 at 30 min, 10/90 at 31 
min, 10/90 at 38 min and finally 97/3 at 39 min. Con-
centrations of tested compounds were determined, based 
on the chromatographic data of the standards. The cali-
bration curves (peak area vs. concentration) for individual 
compounds were obtained for a wide concentration range. 
Analyses of each extract were done in triplicates. The 
concentration of each substance was expressed in mg g–1 
of dry extract. Retention times were: 3.74 min for gallic 
acid; 10.722 min for catechin; 13.272 min for caffeic 
acid; 14.385 min for vanillin; 17.457 min for epicatechin; 
20.213 min for p-cumaric acid; 25.125 min for ferulic 
acid; 26.074 min for taxifolin. 
 
Determination of Proanthocyanidins (PA) Content 
The proanthocyanidins were determined by hydrochlo-
ric acid–butanol method.10 Ten milligram of pine bark 
extract was dissolved in 10 ml of water. To 0.20 ml of 
this solution 3 ml of a 95 % solution of n-butanol /HCl 
(95/5; v/v) was added, followed by addition of 0.1 ml of 
a 1.4 % (w/v) Fe(SO4)  7 H2O in 2 M HCl. The tubes 
were incubated for 40 min at 95 °C. After incubation, the 
samples were cooled and analyzed by measuring absorb-
ance at 550 nm. Cyanidin chloride (Sigma-Aldrich, 
Germany) was used as a standard. The final PA in pine 
bark extracts was expressed on a dry basis (mg/gDW) 
and data were shown as a mean value of three biological 
and three technical replicates ± SE. 
 
Bacterial Strains 
Antibacterial activity of PABE against two different 
isolates of A. baumannii with affiliation to European 
clone I (EU I) and II (EU II) was tested and compared. 
Clinical isolates of A. baumannii were collected during 
two different outbreaks, first from 2002–2007 (EU I) 
and second from 2009–2010 (EU II) in Clinical Hospital 
Center Split, Croatia,7,8 a referral hospital for a wide 
area of southern Croatia. Isolation of A. baumannii was 
performed on blood agar plates (Bio Rad). Initial identi-
fication was made using the ATB 32GN and Vitek 2 sys-
tems (bioMerieux, Marcy-l’Etoile, France) according to 
Clinical and Laboratory Standards Institute recommenda-
tions, CLSI.11 Susceptibility to β-lactams (ceftazidime, cef-
triaxone, cefepime, imipenem, meropenem), β-lactam/ 
β-lactamase inhibitor combinations (ampicillin /sulbac-
tam, piperacillin/ tazobactam), aminoglycosides (amika-
cin, gentamicin) and fluoroquinolones (ciprofloxacin) 
was determined by disc-diffusion tests, and susceptibil-
ity to colistin by E-tests (AB Biodisk, Solna, Sweden). 
MICs were determined by broth microdilution accord-
ing to CLSI.11 Isolate from EU clone II was resistant to 
all antimicrobials (imipenem MIC 64 μg ml–1, mero-
penem 128 μg ml–1, amikacin 64 μg ml–1, gentamicin 64 
μg ml–1, ceftazidime 256 μg ml–1, cefepime 128 μg ml–1, 
ciprofloxacin 32 μg ml–1, piperacillin /tazobactam 128 
μg ml–1 and ceftriaxone 256 μg ml–1) except colistin 
(MIC: 0.5 mg ml–1) and ampicillin /sulbactam (MIC: 1 
mg ml–1). Isolate from EU clone I had lower minimum 
inhibitory concentrations (MIC) for carbapenems (imi-
penem 6 mg ml–1, meropenem 16 mg ml–1) than isolate 
belonging to EU clone II (imipenem and meropenem  
≥ 64 mg ml–1).12 The mechanisms of carbapenem re-
sistance were described previously.7,8 
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Antibacterial Activity Tests 
The antibacterial activities of PABE against isolates of A. 
baumannii belonging to the EU clone I and II were tested 
according to the microdilution method, following the 
CLSI recommendations.11 The bacteria were pre-grown 
on nutrient agar (Biolife, Italy) for 16 h at 36.0 ± 0.1°C to 
obtain the cultures in log phase of growth. The bacterial 
biomass was then suspended in the nutrient broth (Bi-
olife, Italy). For the experiments with powdered extract, 
200, 100, 50, 10 or 1 mg of extract was added into 0.5 ml 
of sterile deionised water and vigorously shaken (40 
Hz/10 min, Kartell TK3S). A 0.5 ml of bacterial suspen-
sion was added in the tubes, which resulted in following 
concentrations of powdered extract: 200, 100, 50, 10 or 1 
mg ml–1. The tubes which served as the positive control 
contained 0.5 ml of bacterial suspension and 0.5 ml of 
sterile deionised water. Both experiments were set in 
triplicate. The tubes were incubated in a dark during 24 h 
at 36.0 ± 0.1 °C with shaking at 120 rpm to assure the 
complete mixing. To confirm the antibacterial activity of 
basic components of extract, the experiments with pure 
caffeic acid, catechin, epicatechin, ferulic acid, gallic 
acid, taxifolin and vanillin solutions in 2 % ethanol were 
set up in triplicate. The tested concentrations of basic 
components were equivalent to those contained in 200 
mg ml–1 of powdered extract. The positive controls were 
set up without and with 2 % of ethanol, which showed no 
difference in the number of bacteria (data not shown).  
The number of viable cells was determined at the 
beginning of experiment and after 24 h of treatment. 
Tubes were vigorously shaken and 0.1 ml of sample was 
plated (spread plate method) directly onto the nutrient 
agar, while another sample was serially diluted (10–1 to 
10–8) and inoculated onto the nutrient agar plates in 
triplicate. The inoculated plates were incubated at 36.0 
± 0.1 °C for 24 h. After the incubation period, the bacte-
rial colonies were counted and the number of viable 
cells was reported as Colony forming units (CFU) ml–1. 
The numbers of CFU were logarithmically transformed. 
The antibacterial activity of the extract, each compound 
and mixture of compounds (caffeic acid, catechin, epi-
catechin, ferulic acid, gallic acid, taxifolin and vanillin) 
was expressed as the reduction of log CFU and as the 
percent reduction of log CFU as compared to the corre-
sponding control. The minimum bactericidal concentra-
tion (MBC) values were determined after 24 h of exper-
iments according to the CLSI directions.11 The mini-
mum inhibitory concentration (MIC) was not deter-
mined due to the turbidity and colour of extracts. The 
comparisons between the numbers of log CFU were 
done using the ANOVA and subsequently the post-hoc 
Duncan test was performed for the calculations concern-
ing pair-wise comparisons. Statistical decisions were 
made at a significance level of p < 0.05. 
RESULTS AND DISCUSSION 
Concentrations of basic substances (determined by 
HPLC) as well as proanthocyanidins were expressed as 
mg g–1 of spray-dried powdered PABE (Table 1). Statis-
tically significant differences in the concentrations of 
basic compounds and proanthocyanidins between ex-
tracts from 3 pooled samples (barks collected from 5 
trees in each sample) were not determined, and there-
fore the extracts were pooled for further experiments/ 
treatments. 
Antibacterial activities of PABE against isolates of 
A. baumannii belonging to EU clone I and II are shown 
in Table 2. The extract showed antibacterial activity 
with MBC of 200 mg ml–1 against both clones.  
To elucidate which basic components contribute to 
the bactericidal activity of powdered extract at concentra-
tion of 200 mg ml–1, experiments with pure solutions of 
components were performed (Table 3). For clone I caffeic 
acid, catechin, epicatechin, ferulic acid, gallic acid and 
vanillin resulted in statistically significant reduction of 
log CFU as compared to corresponding control, but the 
reduction of log CFU was generally low (0.4–0.9 log 
CFU reduction). The antibacterial activity of basic com-
ponents against clone II (Table 3) was similar to those 
against clone I, except that the ferulic acid had no anti-
bacterial activity against clone II. When basic substances 
were tested together against two clones of A. baumannii, 
the reductions of log CFU were 36.9 and 23.5 % for 
clone I and II, respectively. These results suggest that 
besides tested substances, some other substances such as 
proanthocyanidins, which were present in quite a large 
amount in the extract (Table 1), might have contributed to 
the antibacterial activity of extract, too. 
Table 1. Concentrations of basic substances and proanthocya-
nidins in Pinus pinaster aqueous bark extract (PABE) ex-
pressed as mg g–1 of spray-dried powdered PABE. Data shown 
are mean values of three biological and three technical repli-
cates ± SE. 
Basic component Concentration / mg g
–1 in  
P. pinaster bark extract (PABE) 
caffeic acid 0.5 ± 0.03 
catechin 5.5 ± 0.7 
epicatechin 0.7 ± 0.02 
ferulic acid 1.13 ± 0.16 
gallic acid 0.27 ± 0.03 
taxifolin 2.4 ± 0.32 
vanillin 0.42 ± 0.05 
proanthocyanidins 38.1 ± 2.8 
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Several research groups published the results on 
antimicrobial activity of PBEs. As opposed to simple 
aqueous extract (PABE) which was used in this re-
search, in those researches mostly Pycnogenol® - com-
mercial water/ethanol extract was tested and it was 
shown that 250 μg ml–1 of Pycnogenol® counteracted 
the growth of several tested Gram-positive and Gram-
negative bacteria,13 inhibited growth of Helicobacter 
pylori in suspension (12.5 μg ml–1), while in ten times 
higher concentration reduced the adherence of the bac-
terium to gastric cells.14 However its efficiency against 
A. baumannii was not tested. Grimm et al.15,16 showed 
that substances which are basic components of PBE are 
quickly absorbed after oral ingestion and their distribu-
tion in the body tissues is fast. Fourteen hours after 
volunteers were given 300 mg or 200 mg of PBE,  
fifteen compounds from PBE were detected in the  
their plasma.15,16 Maximum concentrations of four iden-
tified compounds in the plasma; catechin, caffeic acid, 
ferulic acid and taxifolin were 107 ng ml–1, 17 ng ml–1, 
15 ng ml–1 and 33 ng ml–1, respectively. Of those four 
substances, caffeic acid and catechin revealed antibacte-
rial activity against A. baumannii clones in our research, 
but epicatechin, gallic acid and vanillin also contributed 
to the activity of PABE against both clones of A. bau-
manii, while ferulic acid slightly contributed to the 
activity of PABE against EU clone I. The above men-
tioned substances are known to possess antimicrobial 
activity against different pathogens. Vanillin is proved 
to express antifungal activity17 and antibacterial activity 
against Cronobacter species;18,19 catechin was effective 
against pathogenic bacteria, Escherichia coli O157:H7, 
Pseudomonas aeruginosa and the food spoilage fungus 
Penicillium chrysogenum20,21 and, it also showed syner-
gistic antibacterial effect with antibiotics.22 Further-
more, the combination of catechin and epicatechin gal-
late potentiated the activity of beta-lactam antibiotics 
against methicillin-resistant Staphylococcus aureus.23 
Furthermore, epicatechin showed synergistic effect with 
the aflavin against clinical isolates of A. baumannii and 
Stenotrophomonas maltophilia.24 Caffeic acid is also 
known to exhibit antimicrobial activity, however its con-
centration in PABE was 0.05 % making it even less con-
centrated in solution which was applied to A. baumannii, 
Table 3. Reduction in the number of A. baumannii isolates belonging to European clone I and II after 24 h of treatment with basic 
components of Pinus pinaster bark extract (in concentration contained in 200 mg ml–1 of powdered extract) as compared to the 
corresponding control. c0 A. baumannii clone I (107 CFU ml–1) = 7.35 ± 0.92; c0 A. baumannii clone II (107 CFU ml–1) = 4.90 ± 
0.14. Data shown are mean values of three biological and three technical replicates ± SE. 
Component Concentration / µg ml–1 
A. baumannii clone I A. baumannii clone II 
Reduction log CFU Reduction / % Reduction log CFU Reduction / % 
Caffeic acid 100    0.5 ± 0.0(a)   5.6 ± 0.5   0.3 ± 0.1(a)  3.9 ± 1.0 
Catechin 110    0.9 ± 0.0(a)   9.7 ± 0.1   0.1 ± 0.0(a)  1.2 ± 0.1 
Epicatechin 140    0.4 ± 0.0(a)   4.5 ± 0.1   0.3 ± 0.0(a)  3.3 ± 0.0 
Ferulic acid 226    0.6 ± 0.0(a)   6.2 ± 0.4 0.0 ± 0.0 –0.1 ± 0.1 
Gallic acid 54    0.4 ± 0.0(a)   4.3 ± 0.3    0.8 ± 0.0(a)   8.7 ± 0.2 
Taxifolin 400 0.1 ± 0.0   0.9 ± 0.2 0.0 ± 0.0   0.0 ± 0.1 
Vanillin 84    0.5 ± 0.0(a)   6.2 ± 0.1   0.3 ± 0.0(a)   3.4 ± 0.1 
All components     3.4 ± 0.0(a) 36.9 ± 0.2   2.2 ± 0.0(a)  23.5 ± 0.0 
(a) significantly different as compared to control 
Table 2. Reduction in the number of A. baumannii isolates belonging to European clone I and II after 24 h of treatment with 
Pinus pinaster aqueous bark extract as compared to the corresponding control. c0 A. baumannii clone I (107 CFU ml–1) = 2.93 ± 
0.57; c0 A. baumannii clone II (107 CFU ml–1) = 1.54 ± 0.26. Bactericidal activity was obtained at 200 mg ml–1, and antibacterial 
activity at 10 mg ml–1. Data shown are mean values of three biological and three technical replicates ± SE. 
Pine extract / 
mg ml–1 
A. baumannii clone I A. baumannii clone II 
Reduction log CFU Reduction / % Reduction log CFU Reduction / % 
200    8.3 ± 0.1(a) 100.0 ± 0.0   8.9 ± 0.1(a) 100.0 ± 0.0 
100    7.1 ± 0.1(a)   85.8 ± 2.5   8.0 ± 0.2(a)   90.2 ± 1.7 
50    6.5 ± 0.1(a)   78.5 ± 1.1   7.0 ± 0.1(a)   78.6 ± 1.2 
10    6.0 ± 0.1(a)   66.3 ± 2.5   6.4 ± 0.1(a)    69.8 ± 0.7 
1 0.2 ± 0.2     2.4 ± 0.7 0.2 ± 0.1      2.1 ± 0.3 
(a) significant reduction as compared to control. 
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and it was reported previously that concentrations high-
er than 0.4 % were needed to inhibit the growth of some 
microorganisms, including L. monocytogenes, E. coli, 
and S. aureus.25 Gallic acid which also contributed to 
antibacterial activity of PABE is a basic constituent of 
many other plant extracts. Tea extracts which contain 
gallic acid and catechins proved to be effective against 
H. pylori without affecting beneficial bacteria.26 These 
data suggest that PABE or its components like gallic 
acid and catechin could not only be efficient against 
MDR A. baumannii, but they could also be used in 
combination with probiotic bacteria. In our research the 
tested in vitro concentrations of basic PABE compo-
nents that showed antibacterial activity against A. bau-
mannii were at least three orders of the magnitude high-
er than the concentration of substances found in plasma 
of patients after oral ingestion of the same quantity of 
PBE.15,16 Therefore, the concern exists that the concen-
tration of the bioactive substances in plasma of patients 
would not be high enough to treat bacteraemia, but  
since A. baumannii causes also skin and wound infec-
tions,27,28,29 application of PABE in sufficient concentra-
tion in such cases is certainly possible. Except investi-
gated basic substances, proanthocyanidins that were 
determined in PABE could have also contributed to the 
antibacterial activity. In grape seeds, proanthocyanidins 
were determined as active antibacterial agents toward 
10 different pathogenic Gram-positive and Gram-nega-
tive bacterial strains.30 Plant-derived proanthocyanidins 
may inhibit the growth of pathogenic bacteria by bind-
ing strongly to proteins at bacterial cell surfaces.31  
In this research we revealed that PABE at the con-
centration 200 mg ml–1 showed bactericidal activity 
against two MDR clinical isolates of A. baumannii be-
longing to EU clone I and II and antibacterial activity at 
lower concentrations, in vitro. This finding suggests that 
PABE and its components could potentially find an 
application in treatment of MDR A. baumannii-infected 
patients. 
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